· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2022 / N 2 Современные возможности лечения тромбозов, ассоциированных с онкологическими заболеваниями Т.В. Вавилова Список литературы/References 1. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. British Journal of Cancer. 2010;103(7):947-953. DOI: 10.1038/sj.bjc.6605883 2. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Practice and Research in Clinical Haematology. 2009;22:49-60. DOI: 10.1016/j.beha.2008.12.009 3. Kozwich DL, Kramer LC, Mielicki WP, Fotopoulos SS, Gordon SG. Application of cancer procoagulant as an early detection tumor marker. Cancer. 1994;74(4):1367-1376. DOI: 10.1002/1097-0142(19940815)74:4<1367::aid-cncr2820740430>3.0.co;2-y. 4. Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G. Procoagulant factors in patients with cancer. Hematology (Amsterdam, Netherlands). 2007;12(6):555-559. DOI: 10.1080/10245330701521416 5. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circulation Research. 2011;108(10):1284-1297. DOI: 10.1161/CIRCRESAHA.110.233056 6. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. The Lancet. Oncology. 2022;23(7):e334-e347. DOI: 10.1016/S1470-2045(22)00160-7 7. Hisada Y, Mackman N. Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models. Hematology. American Society of Hematology. Educational Program. 2019;2019(1):182-186. DOI: 10.1182/hematology.2019000025 8. Tawil N, Bassawon R, Meehan B, Nehme A, Montermini L, Gayden T, De Jay N, Spinelli C, Chennakrishnaiah S, Choi D, Adnani L, Zeinieh M, Jabado N, Kleinman CL, Witcher M, Riazalhosseini Y, Key NS, Schiff D, Grover SP, Mackman N, Couturier CP, Petrecca K, Suvà ML, Patel A, Tirosh I, Najafabadi H, Rak J. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Advances.2021;5(6):1682-1694. DOI: 10.1182/bloodadvances.2020002998 9. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. DOI: 10.1126/science.aau6977 10. Hisada Y, Garratt KB, Maqsood A, Grover SP, Kawano T, Cooley BC, Erlich J, Moik F, Flick MJ, Pabinger I, Mackman N, Ay C. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Advances. 2021;5(2):487-495. DOI: 10.1182/bloodadvances.2020003149 11. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Investigation. 2009;27(Suppl 1):63-74. DOI: 10.1080/07357900802656681 12. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. DOI: 10.1182/blood-2007-10-116327 13. Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, Smit K, Büller HR, van Es N; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-1287. DOI: 10.3324/haematol.2018.209114 14. Noble SIR, Johnson MJ, Lee AYY. Venous thromboembolism in advanced disease: a clinical guide. Oxford University Press; 2008: 9-28. 15. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648-655. DOI: 10.1002/cncr.27772 16. Monreal M, Falgá C, Valdés M, Suárez C, Gabriel F, Tolosa C, Montes J; Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. Journal of Thrombosis and Haemostasis. 2006;4(9):1950-1956. DOI: 10.1111/j.1538-7836.2006.02082.x. 17. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, Büller HR, Sørensen HT. Venous thromboembolism in cancer patients: a population-base cohort study. Blood. 2021;137(14):1959-1969. DOI: 10.1182/blood.2020007338 18. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. The New England Journal of Medicine. 2003;349(2):146-153. DOI: 10.1056/NEJMoa025313 19. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet. Oncology. 2016;17(10):e452-e466. DOI: 10.1016/S1470-2045(16)30369-2 20. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. The New England Journal of Medicine. 2019;380(8):711-719. DOI: 10.1056/NEJMoa1814468 21. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism. The ADAM VTE trial. Journal of Thrombosis and Haemostasis. 2020;18(2):411-421. DOI: 10.1111/jth.14662 22. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. The New England Journal of Medicine. 2020;382(17):1599-1607. DOI: 10.1056/NEJMoa1915103 23. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O’Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. The New England Journal of Medicine. 2019;380(8):720-728. DOI: 10.1056/NEJMoa1814630 24. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology. 2018;36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034 25. Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I, Pernod G, Elias A, Couturaud F, Falvo N, Sevestre MA, Ray V, Burnod A, Brebion N, Roy PM, Timar-David M, Aquilanti S, Constans J, Bura-Rivière A, Brisot D, Chatellier G, Sanchez O, Meyer G, Girard P, Mismetti P; CASTA DIVA Trial Investigators. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781-790. DOI: 10.1016/j.chest.2021.09.037 26. Schrag D, Uno H, Pam R, Rosovsky G, Rutherford C, Sanfilippo KM, Villano JL, Drescher MR, Jayaram NH, Holmes CE, Feldman L, Zattra O, Cronin C, Basch E, Weiss A, Connors J. The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: the CANVAS pragmatic randomized trial. Journal of Clinical Oncology. 2021;39:12020. DOI: 10.1200/JCO.2021.39.15_SUPPL.12020 27. Canonico ME, Santoro C, Avvedimento M, Giugliano G, Mandoli GE, Prastaro M, Franzone A, Piccolo R, Ilardi R, Cameli M, Esposito G. Venous thromboembolism and cancer: a comprehensive review from pathophysiology to novel treatment. Biomolecules. 2022;12(2):259. DOI: 10.3390/biom12020259 28. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. Journal of Clinical Oncology. 2020;38(5):496-520. DOI: 10.1200/JCO.19.01461 29. Wojtukiewicz MZ, Skalij P, Tokajuk P, Politynska B, Wojtukiewicz AM, Tucker SC, Honn KV. Direct oral anticoagulants in cancer patients. Time for a change in paradigm. Cancers (Basel). 2020;12(5):1144. DOI: 10.3390/cancers12051144 30. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis. 2015 Dec;13(12):2187-2191. DOI: 10.1111/jth.13153 31. National Comprehensive Cancer Network®. NCCN Guidelines Version 1.2022. Cancer-associated venous thromboembolic disease. Accessed 2022 Sep 05. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1423 32. Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021 Dec;160(6):2247-2259. DOI: https//doi.org/10.1016/j.chest.2021.07.056 33. Федин А.И., Ермошкина Н.Ю., Путилина М.В., Васильев Ю.Д., Козлов М.Б., Сидельникова Л.В., Снигерева Т.Ю. Особенности клиники и диагностики церебральных венозных тромбозов. Клиническая физиология кровообращения. 2014;1:32-43. [Fedin AI, Yermoshkina NYu, Putilina MV, Vasilyev YuD, Kozlov MB, Sidelnikova LV, Snigereva TYu. Clinical and diagnostic features of cerebral venous thrombosis. Clinical Physiology of Circulation. 2014;1:32-43. (In Russ.).] 34. Li A, Kuderer NM, Garcia DA, Khorana AA, Wells PS, Carrier M, Lyman GH. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2019;17(12):2141-2151. DOI: 10.1111/jth.14613 35. Ассоциация флебологов России. Клинические рекомендации. Тромбоз глубоких вен конечностей. Предварительная версия (проект). Ссылка активна на 05.09.2022. [Russian Association of Phlebologists. Clinical recommendations. Deep vein thrombosis of the extremities. Preliminary version (draft). (In Russ.).] https://phlebounion.ru/files/uploads/rek-afr/DVT%202022/%D0%9A%D0%A0%20%D0%A2%D0%93%D0%92%202022%20%D0%B4%D0%BB%D1%8F%20%D0%9C%D0%97%20%D0%A0%D0%A4%20public%202022.03.30.pdf 36. Сомонова О.В., Антух Э.А., Долгушин Б.И., Елизарова А.Л., Сельчук В.Ю., Черкасов В.А. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли. 2019;9(3s2):668-677. [Somonova OV, Antukh EA, Dolgushin BI, Yelizarova AL, Selchuk VYu, Cherkasov VA. Practical recommendations for prevention and treatment of thromboembolic complications in cancer patients. Malignant Tumors. 2019;9(3 Suppl 2):668-677. (In Russ.).] DOI: 10.18027 / 2224-5057-2019-9-3s2-668-677    [ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]